{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:29:23Z","timestamp":1790958563254,"version":"4.1.0"},"reference-count":107,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Mesothelin (MSLN) is a protein expressed in the mesothelial cell lining of the pleura, peritoneum, and pericardium; its biological functions in normal cells are still unknown. Experimental studies using knockout mice have suggested that this molecule does not play an important role in development and reproduction. In contrast, it has been observed that this molecule is produced in abnormal amounts in several malignant neoplasms, such as mesotheliomas and pancreatic adenocarcinomas. Many molecular studies have also demonstrated that mesothelin is overexpressed in HSOCs. Here, we discuss the current knowledge of mesothelin and focus on its role in clinical and pathological diagnoses, as well as its impact on the prognosis of HSOC. Moreover, regarding the binding of MSLN to the ovarian cancer antigen CA125, which has been demonstrated in many studies, we also report on signal transduction pathways that may play an important role in the spread and neoplastic progression of this lethal neoplasm. Given that mesothelin is overexpressed in many solid tumours and has antigenic properties, this molecule could be considered an antigenic target for the treatment of many malignancies. Consequently, we also review the literature to report on mesothelin-targeting therapies for HSOC that have been recently investigated in many clinical studies.<\/jats:p>","DOI":"10.3390\/cancers14092283","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T08:26:35Z","timestamp":1651566395000},"page":"2283","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impacts on Diagnosis, Prognosis, and Therapeutic Targets"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4357-1287","authenticated-orcid":false,"given":"Giovanna","family":"Giordano","sequence":"first","affiliation":[{"name":"Pathology Unit, Department of Medicine and Surgery, University of Parma, Viale A. Gramsci, 14, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5012-7008","authenticated-orcid":false,"given":"Elena","family":"Ferioli","sequence":"additional","affiliation":[{"name":"Pathology Unit, Department of Medicine and Surgery, University of Parma, Viale A. Gramsci, 14, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0183-757X","authenticated-orcid":false,"given":"Alessandro","family":"Tafuni","sequence":"additional","affiliation":[{"name":"Pathology Unit, Department of Medicine and Surgery, University of Parma, Viale A. Gramsci, 14, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"21984","DOI":"10.1074\/jbc.270.37.21984","article-title":"Molecular cloning and expression of megakaryocyte potentiating factor cDNA","volume":"270","author":"Kojima","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is not required for normal mouse development or reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1871520611313020014","article-title":"The role of mesothelin in tumor progression and targeted therapy","volume":"13","author":"Tang","year":"2013","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cncr.22781","article-title":"Generation and characterization of an ascitogenic mesothelin-expressing tumor model","volume":"110","author":"Cheng","year":"2007","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.gt.3302974","article-title":"Control of human mesothelin-expressing tumors by DNA vaccines","volume":"14","author":"Chang","year":"2007","journal-title":"Gene Ther."},{"key":"ref_9","unstructured":"American Cancer Society (2012). Cancer Facts & Figures, American Cancer Society."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-07-0629","article-title":"Clinical significance of sera mesothelin in patients with mesothelioma and lung cancer","volume":"13","author":"Cristaudo","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/0959-8049(94)00356-A","article-title":"Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease","volume":"30","author":"Berruti","year":"1994","journal-title":"Eur. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000050620","article-title":"Elevated CA125 in breast cancer a sign of advanced disease","volume":"22","author":"Norum","year":"2000","journal-title":"Tumour Biol."},{"key":"ref_13","first-page":"531","article-title":"Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as sera markers in malignant mesothelioma","volume":"23","author":"Hedman","year":"2003","journal-title":"Anticancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1080\/1042819031000104079","article-title":"Serum CA 125 as a prognostic factor in non-Hodgkin\u2019s lymphoma","volume":"44","author":"Bairey","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<755::AID-CNCR27>3.0.CO;2-O","article-title":"Serum CA 125 is of clinical value in the staging and follow-up of patients with non- Hodgkin\u2019s lymphoma: Correlation with tumor parameters and disease activity","volume":"85","author":"Burney","year":"1999","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1634\/theoncologist.9-4-417","article-title":"Serum CA 125: A tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin\u2019s lymphoma","volume":"9","author":"Zidan","year":"2004","journal-title":"Oncologist"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00432-006-0189-2","article-title":"Peritoneal lavage CEA\/CA125 is a prognostic factor for gastric cancer patients","volume":"33","author":"Yamamoto","year":"2007","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.humrep.a136832","article-title":"The CA 125 tumour-associated antigen: A review of the literature","volume":"4","author":"Jacobs","year":"1989","journal-title":"Hum. Reprod."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0090-8258(88)90039-X","article-title":"An initial analysis of pre-operative serum CA125 levels in patients with early stage ovarian carcinoma","volume":"30","author":"Zurawski","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0889-8588(18)30313-7","article-title":"Ovarian cancer: Early diagnosis and screening","volume":"6","author":"Einhorn","year":"1992","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of mesothelin immunostaining in tumor diagnosis","volume":"27","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"11531","DOI":"10.1073\/pnas.96.20.11531","article-title":"Soluble member(s) of the mesothelin\/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma","volume":"96","author":"Scholler","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00404-013-3128-x","article-title":"Serum soluble mesothelin-related peptide (SMRP): A potential diagnostic and monitoring marker for epithelial ovarian cancer","volume":"289","author":"Wu","year":"2014","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_24","first-page":"1010428318804937","article-title":"Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients","volume":"40","author":"Czerwonka","year":"2018","journal-title":"Tumour Biol."},{"key":"ref_25","first-page":"4721","article-title":"Serum mesothelin in epithelial ovarian carcinoma: A new screening marker and prognostic factor","volume":"26","author":"Huang","year":"2006","journal-title":"Anticancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ygyno.2007.04.022","article-title":"Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment","volume":"106","author":"Badgwell","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1517\/17530059.2011.559459","article-title":"Two novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma","volume":"5","author":"Hellstrom","year":"2011","journal-title":"Expert Opin. Med. Diagn."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e1700135","DOI":"10.1002\/prca.201700135","article-title":"Discovery and validation of novel protein biomarkers in ovarian cancer patient urine","volume":"12","author":"Sandow","year":"2018","journal-title":"Proteom. Clin. Appl."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.cllc.2011.12.004","article-title":"Mesothelin levels in urine are affected by glomerular leakage and tubular reabsorption","volume":"13","author":"Hollevoet","year":"2012","journal-title":"Clin. Lung Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1166\/jbn.2015.2063","article-title":"Anti-mesothelin nanobodies for both conventional and nanoparticle-based biomedical applications","volume":"11","author":"Prantner","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1021\/acs.molpharmaceut.7b00789","article-title":"Molecular imaging of mesothelin-expressing ovarian cancer with a human and mouse cross reactive nanobody","volume":"15","author":"Prantner","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1158\/1535-7163.MCT-14-0487-T","article-title":"An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models","volume":"13","author":"Scales","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1158\/1078-0432.CCR-15-1272","article-title":"ImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody-drug conjugate treatment","volume":"22","author":"Lamberts","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1535-7163.MCT-16-0449","article-title":"Preclinical efficacy of an antibody-drug conjugate targeting mesothelin correlates with quantitative 89Zr-ImmunoPET","volume":"16","author":"Ogasawara","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/PGP.0b013e31817d5340","article-title":"Distinguishing breast carcinoma from M\u00fcllerian serous carcinoma with mammaglobin and mesothelin","volume":"27","author":"Kanner","year":"2008","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Weidemann, S., Gagelmann, P., Gorbokon, N., Lennartz, M., Menz, A., Luebke, A.M., Kluth, M., Hube-Magg, C., Blessin, N.C., and Fraune, C. (2021). Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors. Biomedicines, 9.","DOI":"10.3390\/biomedicines9040397"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/sj.bjc.6604964","article-title":"High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma","volume":"100","author":"Cheng","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_38","first-page":"1549","article-title":"High expression of mesothelin in advanced serous ovarian cancer is associated with poor prognosis","volume":"24","author":"Yildiz","year":"2019","journal-title":"J. BUON"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/1078-0432.CCR-05-1397","article-title":"Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma","volume":"12","author":"Yen","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"11694","DOI":"10.18632\/oncotarget.3429","article-title":"High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis","volume":"6","author":"Thomas","year":"2015","journal-title":"Oncotarget"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1097\/MPA.0b013e318221bed8","article-title":"Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma","volume":"40","author":"Einama","year":"2011","journal-title":"Pancreas"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1007\/s12325-020-01520-w","article-title":"Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c+ Expression in Tumor","volume":"37","author":"Magalhaes","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/bjc.2012.235","article-title":"Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer","volume":"107","author":"Einama","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.3892\/ijo.2012.1662","article-title":"Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer","volume":"41","author":"Kawamata","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3892\/ol.2020.12055","article-title":"Membrane mesothelin expression positivity is associated with poor clinical outcome of luminal-type breast cancer","volume":"20","author":"Suzuki","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s12253-020-00823-1","article-title":"Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma","volume":"26","author":"Kakimoto","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.6004\/jnccn.2017.0003","article-title":"NCCN Guidelines Insights: Genetic\/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017","volume":"15","author":"Daly","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2005.01.039","article-title":"Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations","volume":"97","author":"Casey","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"954","DOI":"10.3389\/fonc.2020.00954","article-title":"Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer","volume":"10","author":"Jiang","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GCO.0b013e328011a21f","article-title":"The distal fallopian tube: A new model for pelvic serous carcinogenesis","volume":"19","author":"Crum","year":"2007","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/GRF.0000000000000316","article-title":"Management of Preinvasive Lesions","volume":"60","author":"Patrono","year":"2017","journal-title":"Clin. Obstet. Gynecol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.pap.0000201826.46978.e5","article-title":"Advances in the recognition of tubal intraepithelial carcinoma: Applications to cancer screening and the pathogenesis of ovarian cancer","volume":"13","author":"Lee","year":"2006","journal-title":"Adv. Anat. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.canlet.2006.03.029","article-title":"Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery","volume":"247","author":"Scholler","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1515\/hsz-2014-0155","article-title":"Membrane-type I matrixmetalloproteinase-dependent ectodomain shedding of mucin16\/CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium","volume":"395","author":"Bruney","year":"2014","journal-title":"Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa020809","article-title":"Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells","volume":"348","author":"Selgas","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/path.4281","article-title":"Carcinoma-associated fibroblasts derive from mesothelial cells via mesothelial-to-mesenchymal transition in peritoneal metastasis","volume":"231","author":"Sandoval","year":"2013","journal-title":"J. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/cr.2009.5","article-title":"TGF-beta-induced epithelial to mesenchymal transition","volume":"19","author":"Xu","year":"2009","journal-title":"Cell Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1002\/ijc.24901","article-title":"Snail is critical for tumor growth and metastasis of ovarian carcinoma","volume":"126","author":"Jin","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Carey, P., Low, E., Harper, E., and Stack, M.S. (2021). Metalloproteinases in Ovarian Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073403"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"50015","DOI":"10.18632\/oncotarget.18388","article-title":"The effect of CA125 on metastasis of ovarian cancer: Old marker new function","volume":"8","author":"Yuan","year":"2017","journal-title":"Oncotarget"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/aogs.13179","article-title":"ZEB1 expression is a potential indicator of invasive endometriosis","volume":"96","author":"Furuya","year":"2017","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/sj.bjc.6603533","article-title":"Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients","volume":"96","author":"Hosono","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Yang, J., Zhou, Y., Ng, S.K., Huang, K.C., Ni, X., Choi, P.W., Hasselblatt, K., Muto, M.G., Welch, W.R., and Berkowitz, R.S. (2017). Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3417-z"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"48820","DOI":"10.18632\/oncotarget.16179","article-title":"EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy","volume":"8","author":"Wimberger","year":"2017","journal-title":"Oncotarget"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"574","DOI":"10.7150\/ijbs.52097","article-title":"Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3\/FOXO3 pathway","volume":"17","author":"Huo","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12943-018-0856-3","article-title":"Critical role of FOXO3a in carcinogenesis","volume":"17","author":"Liu","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1002\/jcp.26235","article-title":"Synergistic effect of HIF-1alpha and FoxO3a trigger cardiomyocyte apoptosis under hyperglycemic ischemia condition","volume":"233","author":"Chen","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1083\/jcb.200303026","article-title":"FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons","volume":"162","author":"Gilley","year":"2003","journal-title":"J. Cell Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.stemcr.2016.06.006","article-title":"Glucose-induced oxidative stress reduces proliferation in embryonic stem cells via FOXO3A\/beta-catenin-dependent transcription of p21(cip1)","volume":"7","author":"Satoorian","year":"2016","journal-title":"Stem Cell Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1465-9921-14-68","article-title":"Platelet-derived growth factor-a regulates lung fibroblast S-phase entry through p27(kip1) and FoxO3a","volume":"14","author":"McGowan","year":"2013","journal-title":"Respir. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"12748","DOI":"10.1038\/ncomms12748","article-title":"Inhibition of ROS and upregulation of inflammatory cytokines by FoxO3a promotes survival against Salmonella typhimurium","volume":"7","author":"Joseph","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrclinonc.2015.224","article-title":"Can advanced-stage ovarian cancer be cured?","volume":"13","author":"Narod","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2147\/OTT.S155581","article-title":"The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: An updated systematic review and meta-analysis","volume":"11","author":"Ruan","year":"2018","journal-title":"Onco Targets Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.18.02050","article-title":"Moving from poly (ADP-Ribose) polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy","volume":"37","author":"Gourley","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc1891","article-title":"Immunotoxin therapy of cancer","volume":"6","author":"Pastan","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_77","first-page":"3520","article-title":"Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro","volume":"8","author":"Hassan","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/cncr.28875","article-title":"Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125","volume":"120","author":"Hassan","year":"2014","journal-title":"Cancer"},{"key":"ref_79","first-page":"208ra147","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"23","author":"Hassan","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_80","first-page":"20","article-title":"Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin","volume":"7","author":"Hassan","year":"2007","journal-title":"Cancer Immun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.lungcan.2009.07.016","article-title":"Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy","volume":"68","author":"Hassan","year":"2010","journal-title":"Lung Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin expressing cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: A novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Chen, H., Lin, Z., Arnst, K.E., Miller, D.D., and Li, W. (2017). Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. Molecules, 22.","DOI":"10.3390\/molecules22081281"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13046-017-0667-1","article-title":"Fate of Antibody-Drug Conjugates in Cancer Cells","volume":"37","author":"Chalouni","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"34103","DOI":"10.18632\/oncotarget.26135","article-title":"Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expression human ovarian cancer models","volume":"9","author":"Quanz","year":"2018","journal-title":"Oncotarget"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1089\/hum.2017.080","article-title":"Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy","volume":"29","author":"Hung","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/mt.2011.256","article-title":"Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor","volume":"20","author":"Sandaltzopoulos","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ygyno.2020.12.005","article-title":"Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer","volume":"160","author":"Banville","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-018-0568-6","article-title":"Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: Lessons learned and strategies for moving forward","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"27359","DOI":"10.18632\/oncotarget.4751","article-title":"LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model","volume":"6","author":"Huang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1073\/pnas.1003345107","article-title":"Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer","volume":"107","author":"Matsuzaki","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1158\/0008-5472.CAN-20-2701","article-title":"Mesothelin-Specific CAR T Cells Target Ovarian Cancer","volume":"81","author":"Schoutrop","year":"2021","journal-title":"Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CJI.0000000000000160","article-title":"Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells","volume":"40","author":"Tanyi","year":"2017","journal-title":"J. Immunother."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","article-title":"Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy","volume":"9","author":"Hu","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrmicro.2017.126","article-title":"Listeria monocytogenes: Towards a complete picture of its physiology and pathogenesis","volume":"16","author":"Radoshevich","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"642316","DOI":"10.3389\/fimmu.2021.642316","article-title":"Clinical Experience and Recent Advances in the Development of Listeria-Based Tumor Immunotherapies","volume":"12","author":"Oladejo","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","article-title":"A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: Phase I studies of safety and immune induction","volume":"18","author":"Le","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_106","first-page":"1833","article-title":"Correlation of in vivo and in vitro assays of immunocompetence in cancer patients","volume":"34","author":"Golub","year":"1974","journal-title":"Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Flickinger, J.C., Rodeck, U., and Snook, A.E. (2018). Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress. Vaccines, 6.","DOI":"10.3390\/vaccines6030048"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/9\/2283\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:05:43Z","timestamp":1760137543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/9\/2283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":107,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["cancers14092283"],"URL":"https:\/\/doi.org\/10.3390\/cancers14092283","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]}}}